Blog
RSS FeedPosted by Michael Wonder on 05 Oct 2022
Tecentriq (atezolizumab) receives CADTH reimbursement recommendations for the adjuvant treatment of early-stage non-small-cell lung cancer and the treatment of extensive stage small cell lung cancer
5 October 2022 - The CADTH recommendations are a step towards public funding of this treatment option for some patients with ...
Posted by Michael Wonder on 11 Feb 2022
AbbVie announces first provincial reimbursements for Venclexta (venetoclax) in combination with azacitidine for acute myeloid leukaemia patients
10 February 2022 - Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance, Quebec, Saskatchewan, and ...
Posted by Michael Wonder on 18 Jan 2022
Discussion paper and online questionnaire for information session on a potential pan-Canadian formulary
18 January 2022 - On 18 January 2022, the advisory panel and CADTH will host an information session on the panel’s ...
Posted by Michael Wonder on 29 Apr 2021
Bavencio receives reimbursement recommendation from pCODR and INESSS for the maintenance treatment of patients with advanced bladder cancer
29 April 2021 - EMD Serono Canada and Pfizer Canada are pleased to announce that Bavencio (avelumab for injection) has received ...
Posted by Michael Wonder on 29 Oct 2020
CADTH publishes final recommendation for Blincyto
29 October 2020 - The pERC final recommendation is based on a reconsideration of the initial recommendation and feedback from eligible ...
Posted by Michael Wonder on 27 Oct 2020
Sales of cancer medicines in Canada nearly tripled over the past decade
27 October 2020 - Today, the PMPRB, under the National Prescription Drug Utilization Information System (NPDUIS) initiative, released a chartbook ...
Posted by Michael Wonder on 20 Aug 2020
Life saving cystic fibrosis drug still unavailable in Canada
19 August 2020 - Nicole Stringer has been meeting with surgeons about the possibility of having a double-lung transplant. The ...
Posted by Michael Wonder on 17 Oct 2019
Canadian breakthrough that became the world's most expensive drug, then vanished, gets second chance
17 October 2019 - CBC story about how pharmaceutical industry abandoned gene therapy Glybera sparks NRC effort to re-invent it. ...
Posted by Michael Wonder on 16 Dec 2018
Proposal to harmonise, streamline and transition the Cancer Drug Implementation Advisory Committee to CADTH
14 December 2018 - Providing customised implementation support to decision-makers at all levels of the health system is a key ...
Posted by Michael Wonder on 10 Apr 2018
Innovative drugs need a new regulatory approach
10 April 2018 - Innovative drugs help people enjoy longer, healthier, more productive lives. They also allow our health-care systems ...
Posted by Michael Wonder on 16 Feb 2018
Quebec and New Brunswick become first provinces to provide public funding of Ibrance for the first-line treatment of metastatic breast cancer
15 February 2018 - Since Ibrance received Health Canada marketing authorisation in March 2016, Canadian women living with metastatic breast cancer ...
Posted by Michael Wonder on 21 Jan 2018
At $262.40 per pill, the cancer drug that could save her life isn’t covered in B.C.
19 January 2018 - Karen McLaren of Langley has stage four breast cancer, and has been prescribed a drug that could ...
Posted by Michael Wonder on 11 Dec 2017
Desperate families waiting to learn if 'miracle drug' covered
8 December 2017 - When Karolina Figarski gave birth to her daughter, Olivia, the doctors described her as a healthy ...
Posted by Michael Wonder on 23 Nov 2017
Canada-wide program aims to get young cancer patients faster access to new therapies
23 November 2017 - If Terry Fox were diagnosed today, he would fall among the 20 per cent of young ...
Posted by Michael Wonder on 28 Mar 2017
Roche withdraws submission for Avastin
28 March 2017 - Roche was seeking a positive CADTH recommendation for the use of bevacizumab in combination with pemetrexed ...